Total SLAMF6+ TSL in the control group declined substantially from day 12 to day 19.5 (Fig. 5c and Extended Data Fig. 8d), probably due to diminished antigen presentation in the tdLN during late tumour growth. This evidence concerns the gene SLAMF6 and neoplasm.